The main goals of this substudy are to identify who in the substudy has undiagnosed TB and to investigate ways to help predict who is more likely to get TB, such as changes that can be detected in blood samples.

The CoVPN 3008 (Ubuntu) study highlights a significant TB burden among participants, especially those with HIV. Researchers are developing tools like TB biomarkers, transcriptomics, tongue swabs, and AI-analyzed X-rays for earlier, more efficient diagnosis and management, offering hope for high-risk populations.

A Phase 3, randomized, double-blinded, placebo-controlled trial to evaluate the safety, tolerability, and immunogenicity of Respiratory Syncytial Virus (RSV) prefusion F subunit vaccine in pregnant participants living with HIV and their infants.

Respiratory syncytial virus (RSV) is a major threat to infants, causing severe respiratory conditions like bronchiolitis and pneumonia, with heightened risks for HIV-exposed but uninfected infants due to reduced maternal antibody transfer. C Pfizer's bivalent RSV vaccine (RSVpreF) has shown high efficacy in Phase 3 trials, particularly in pregnant women, reducing severe RSV-related infections in infants up to six months old. This study focuses on evaluating RSVpreF's safety and effectiveness in HIV-positive pregnant women, addressing RSV's disproportionate impact on high-risk infants.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.

The Bacille Calmette-Guérin (BCG) vaccine offers limited adult protection, and lengthy treatments contribute to drug-resistant strains. The investigational M72/AS01 E-4 vaccine, showing 50% efficacy in a Phase 2b trial, is being evaluated to confirm safety and efficacy in HIV-positive and HIV-negative populations. If successful, it could transform TB prevention, especially in high-burden regions.

A Phase 2a, Doubke-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral MK8527 Once Monthly in Participants at Low-Risk for HIV-1 Infection.

MK-8527 is a new antiviral being developed for HIV-1 prevention, offering potent activity and a long intracellular half-life suitable for once-monthly (QM) dosing. This approach aims to improve adherence and reduce stigma compared to daily PrEP options like FTC/TDF and FTC/TAF, particularly in high-risk areas like sub-Saharan Africa.

A Phase 2a clinical trial to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa.

The BCG vaccine, the only licensed TB vaccine, offers limited efficacy in adults, highlighting the need for better alternatives. MTBVAC, a promising live attenuated vaccine shows potential for stronger T-cell responses and is currently being tested in diverse populations, including adolescents and people living with HIV. MTBVAC’s development is a crucial step toward an effective TB vaccine, especially for vulnerable groups.

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants.

DOR/ISL (MK-8591A) is a new 2-drug HIV-1 therapy combining Doravirine (DOR), a proven NNRTI, and Islatravir (ISL), an investigational NRTTI. This daily regimen offers potent efficacy, a high resistance barrier, and reduced drug exposure compared to 3-drug regimens, addressing the need for simpler, safer long-term treatments.

A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection.

Adolescent Girls and Young Women (AGYW) in sub-Saharan Africa account for 25% of new HIV infections globally, with 5 in 6 new cases among girls aged 15-19. While daily PrEP (F/TDF) is effective, low adherence due to stigma, side effects, and the daily pill routine has limited its success. New alternatives, like F/TAF (a smaller pill) and lenacapavir (a 6-monthly injection), offer easier, stigma-free protection, potentially revolutionizing HIV prevention for AGYW. These options could reduce new infections and improve PrEP accessibility, offering more hope and empowerment for this high-risk group.